FDA Sends CBD Compliance and Enforcement Policy for White House Review
- The U.S. FDA submitted a notice titled "Cannabidiol (CBD) Products Compliance and Enforcement Policy" for review by the White House Office of Information and Regulatory Affairs on March 13.
- The filing is a pending regulatory review listed on Reginfo.gov and is classified as a notice rather than a formal rule.
- The notice indicates the FDA is advancing a federal compliance and enforcement policy specifically targeting CBD products to clarify regulatory and enforcement plans.
- This development coincides with public anticipation of a final marijuana rescheduling order and Medicare’s upcoming first-ever CBD program, signaling a move toward clearer CBD market oversight.
The U.S. Food and Drug Administration has submitted a notice titled Cannabidiol (CBD) Products Compliance and Enforcement Policy for review by the White House Office of Information and Regulatory Affairs on March 13. The filing is listed on Reginfo.gov as a pending EO 12866 regulatory review, with the action classified as a notice rather than a formal rule. Although the filing does not include the text of the policy itself, the development is notable because it shows the FDA is moving forward with a federal compliance and enforcement document focused specifically on CBD products. It also suggests the agency is working to clarify how it plans to regulate and enforce rules involving these products.
The notice comes as the public awaits a final marijuana rescheduling order, and as Medicare is poised to launch its first-ever CBD program.
For now, the new notice does not reveal what specific standards or priorities the policy would include. But its appearance in the federal review pipeline is a sign that the FDA may soon provide a more defined approach to CBD compliance and enforcement after years of uncertainty surrounding the market.